MERIDIAN BIOSCIENCE, INC.
|
(Exact name of registrant as specified in its charter)
|
Ohio
|
0-14902
|
31-0888197
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No. )
|
3471 River Hills Drive, Cincinnati, Ohio
|
45244
|
(Address of principal executive offices)
|
(Zip Code)
|
(Former name or former address, if changed since last report.)
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
|
Exhibits
|
10.1
|
Employment Agreement between Meridian Bioscience, Inc. and Jack Kenny
|
99.1
|
Press Release of Meridian Bioscience, Inc. dated October 9, 2017
|
MERIDIAN BIOSCIENCE, INC.
|
||
Date: October 11, 2017
|
By: /s/ Melissa A. Lueke
|
|
Executive Vice President and Chief Financial Officer
|
||
(Principal Financial and Accounting Officer)
|
(a)
|
For each fiscal year of the Employment Term, the Executive shall be eligible to earn an annual bonus (the "Annual Bonus") of up to $275,000 for Year 1 and $325,000 for the second twelve (12) months of the employment term ("Year 2"). The actual amount of any Annual Bonus payable to Executive in any year shall be determined by the Compensation Committee of the Board (the "Compensation Committee") based upon performance criteria set forth in advance under the Bonus Plan and the achievement of such performance criteria.
|
(b)
|
The Annual Bonus, if any, will be paid in accordance with the terms of the Bonus Plan established by the Compensation Committee.
|
(c)
|
Except as otherwise provided in Section 5, in order to be eligible to receive an Annual Bonus, the Executive must be employed by the Company on the last day of the applicable fiscal year.
|
(a)
|
In consideration of the Executive entering into this Agreement and as an inducement to join the Company, on the Effective Date, the Company will grant the following equity awards to the Executive pursuant to the Meridian Bioscience, Inc. 2012 Stock Incentive Plan (the "Plan"): (i) options to purchase 100,000 shares of common stock in the Company at an exercise price equal to the fair market value on the date of grant, which shall vest on a pro rata basis over the four (4) years following the Effective Date; (ii) 13,000 restricted stock units which shall vest in a lump sum or "cliff" basis on the second anniversary of the Effective Date. All other terms and conditions of such awards shall be governed by the terms and conditions of the Plan and the applicable award agreements; and
|
(b)
|
In conjunction with the Company's November 2017 management equity awards, 25,000 restricted stock units, which shall vest in a lump sum or "cliff" basis on the fourth anniversary of the Effective Date. Thereafter, with respect to each fiscal year of the Company ending during the Employment Term, the Executive shall be eligible to receive annual equity awards under the Plan or any successor plan; provided that, the Executive shall receive no less than 25,000 restricted stock units per year which shall vest in a lump sum or "cliff" basis on the fourth anniversary following the date of grant. All other terms and conditions of such awards shall be governed by the terms and conditions of the Plan and the applicable award agreements.
|
(a)
|
In the event that the Executive is made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal, administrative, or investigative (a "Proceeding"), other than any Proceeding initiated by the Executive or the Company related to any contest or dispute between the Executive and the Company or any of its affiliates with respect to this Agreement or the Executive's employment hereunder, by reason of the fact that the Executive is or was a director or officer of the Company, or any affiliate of the Company, or is or was serving at the request of the Company as a director, officer, member, employee, or agent of another corporation or a partnership, joint venture, trust, or other enterprise, the Executive shall be indemnified and held harmless by the Company to the maximum extent permitted under applicable law and the Company's Articles of Incorporation and Code of Regulations from and against any liabilities, costs, claims, and expenses, including all costs and expenses incurred in defense of any Proceeding (including attorneys' fees). Costs and expenses incurred by the Executive in defense of such Proceeding (including attorneys' fees) shall be paid by the Company in advance of the final disposition of such litigation upon receipt by the Company of: (i) a written request for payment; (ii) appropriate documentation evidencing the incurrence, amount, and nature of the costs and expenses for which payment is being sought; and (iii) an undertaking adequate under applicable law made by or on behalf of the Executive to repay the amounts so paid if it shall ultimately be determined that the Executive is not entitled to be indemnified by the Company under this Agreement.
|
(b)
|
During the Employment Term and for a period of six (6) years thereafter, the Company or any successor to the Company shall purchase and maintain, at its own expense, directors' and officers' liability insurance providing coverage to the Executive on terms that are no less favorable than the coverage provided to other directors and similarly situated executives of the Company.
|
(a)
|
The Executive's employment hereunder may be terminated upon either party's failure to renew the Agreement in accordance with Section 1, by the Company for Cause or by the Executive without Good Reason. If the Executive's employment is terminated upon either party's failure to renew the Agreement, by the Company for Cause or by the Executive without Good Reason, the Executive shall be entitled to receive:
|
(i)
|
any accrued but unpaid Base Salary and accrued but unused vacation which shall be paid on the pay date immediately following the Termination Date (as defined below) in accordance with the Company's customary payroll procedures;
|
(ii)
|
any earned but unpaid Annual Bonus with respect to any completed fiscal year immediately preceding the Termination Date, which shall be paid on the otherwise applicable payment date; provided that, if the Executive's employment is terminated by the Company for Cause, then any such accrued but unpaid Annual Bonus shall be forfeited;
|
(iii)
|
reimbursement for unreimbursed business expenses properly incurred by the Executive, which shall be subject to and paid in accordance with the Company's expense reimbursement policy; and
|
(iv)
|
such employee benefits (including equity compensation), if any, to which the Executive may be entitled under the Company's employee benefit plans as of the Termination Date; provided that, in no event shall the Executive be entitled to any payments in the nature of severance or termination payments except as specifically provided herein.
|
(b)
|
For purposes of this Agreement, "Cause" shall mean:
|
(i)
|
the Executive's failure to perform his duties (other than any such failure resulting from incapacity due to physical or mental illness);
|
(ii)
|
the Executive's failure to comply with any valid and legal directive of the Board;
|
(iii)
|
the Executive's engagement in dishonesty, illegal conduct, or gross misconduct, which is, in each case, injurious to the Company or its affiliates or Executive's breach of any fiduciary duty or duty of loyalty to Company or any of its subsidiaries or affiliates;
|
(v)
|
the Executive's conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony (or state law equivalent) or a crime that constitutes a misdemeanor involving moral turpitude;
|
(vi)
|
the Executive's willful unauthorized disclosure of Confidential Information (as defined below);
|
(vii)
|
the Executive's material breach of any material obligation under this Agreement or any other written agreement between the Executive and the Company; or
|
(viii)
|
any material failure by the Executive to comply with the Company's written policies or rules, as they may be in effect from time to time during the Employment Term.
|
(c)
|
For purposes of this Agreement, "Good Reason" shall mean the occurrence of any of the following, in each case during the Employment Term without the Executive's written consent:
|
(i)
|
a material reduction in the Executive's Base Salary other than a general reduction in Base Salary that affects all similarly situated executives in substantially the same proportions;
|
(ii)
|
a material reduction in the Executive's Annual Bonus with a target of thirty percent (30%) of Base Salary (the "Target Bonus") opportunity;
|
(iii)
|
a relocation of the Executive's principal place of employment by more than fifty (50) miles;
|
(iv)
|
any material breach by the Company of any material provision of this Agreement or any material provision of any other agreement between the Executive and the Company;
|
(v)
|
the Company's failure to nominate the Executive for election to the Board and to use its best efforts to have him elected and re-elected, as applicable; or
|
(vi)
|
a material, adverse change in the Executive's title, authority, duties, or responsibilities (other than temporarily while the Executive is physically or mentally incapacitated or as required by applicable law).
|
(a)
|
continued Base Salary for one year following the Termination Date payable in equal installments in accordance with the Company's normal payroll practices, but no less frequently than monthly, which shall commence within twenty-eight (28) days following the Termination Date; provided that, if the Release Execution Period begins in one taxable year and ends in another taxable year, payments shall not begin until the beginning of the second taxable year; provided further that, the first installment payment shall include all amounts of Base Salary that would otherwise have been paid to the Executive during the period beginning on the Termination Date and ending on the first payment date if no delay had been imposed;
|
(b)
|
a payment equal to the product of (i) the Annual Bonus, if any, that the Executive would have earned for the fiscal year in which the Termination Date (as determined in accordance with Section 5.6) occurs based on achievement of the applicable performance goals for such year and (ii) a fraction, the numerator of which is the number of days the Executive was employed by the Company during the year of termination and the denominator of which is the number of days in such year (the "Pro-Rata Bonus"). This amount shall be paid on the date that annual bonuses are paid to similarly situated executives, but in no event later than two-and-a-half (2 1/2) months following the end of the fiscal year in which the Termination Date occurs;
|
(c)
|
If the Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA"), the Company shall reimburse the Executive for the difference between the monthly COBRA premium paid by the Executive for himself and his dependents and the monthly premium amount paid by similarly situated active executives. Such reimbursement shall be paid to the Executive on the standard payroll payment date of the month immediately following the month in which the Executive timely remits the premium payment. The Executive shall be eligible to receive such reimbursement until the earliest of: (i) the eighteen-month anniversary of the Termination Date; (ii) the date the Executive is no longer eligible to receive COBRA continuation coverage; and (iii) the date on which the Executive becomes eligible to receive substantially similar coverage from another employer or other source. Notwithstanding the foregoing, if the Company's making payments under this Section 5.2(c) would violate the nondiscrimination rules applicable to non-grandfathered plans under the Affordable Care Act (the "ACA"), or result in the imposition of penalties under the ACA and the related regulations and guidance promulgated thereunder), the parties agree to reform this Section 5.2(c) in a manner as is necessary to comply with the ACA.
|
(d)
|
The treatment of any outstanding equity awards shall be determined in accordance with the terms of the Plan and the applicable award agreements.
|
(a)
|
The Executive's employment hereunder shall terminate automatically upon the Executive's death during the Employment Term, and the Company may terminate the Executive's employment on account of the Executive's Disability.
|
(b)
|
If the Executive's employment is terminated during the Employment Term on account of the Executive's death or Disability, the Executive (or the Executive's estate and/or beneficiaries, as the case may be) shall be entitled to receive the following:
|
(i)
|
the Accrued Amounts; and
|
(ii)
|
a lump sum payment equal to the Pro-Rata Bonus, if any, that the Executive would have earned for the fiscal year in which the Termination Date occurs based on the achievement of applicable performance goals for such year, which shall be payable on the date that annual bonuses are paid to the Company's similarly situated executives, but in no event later than two-and-a-half (2 1/2) months following the end of the fiscal year in which the Termination Date occurs.
|
(c)
|
For purposes of this Agreement, "Disability" shall mean the Executive is entitled to receive long-term disability benefits under the Company's long-term disability plan, or if there is no such plan, the Executive's inability, due to physical or mental incapacity, to perform the essential functions of his job, with or without reasonable accommodation, for one hundred eighty (180) days out of any three hundred sixty-five (365) day period or one hundred twenty (120) consecutive days. Any question as to the existence of the Executive's Disability as to which the Executive and the Company cannot agree shall be determined in writing by a qualified independent physician mutually acceptable to the Executive and the Company. If the Executive and the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company and the Executive shall be final and conclusive for all purposes of this Agreement.
|
(a)
|
Notwithstanding any other provision contained herein, if the Executive's employment hereunder is terminated by the Executive for Good Reason or by the Company on account of its failure to renew the Agreement in accordance with Section 1 or without Cause (other than on account of the Executive's death or Disability), in each case within twenty-four (24) months following a Change in Control, the Executive shall be entitled to receive the Accrued Amounts and subject to the Executive's compliance with Section 6, Section 7, Section 8 and Section 9 of this Agreement and his execution of a Release which becomes effective within twenty-eight (28) days following the Termination Date, the Executive shall be entitled to receive a lump sum cash payment equal to two (2) times the then current Base Salary following the Termination Date payable within sixty (60) days and Target Bonus for the year in which the Termination Date occurs (or if greater, the year immediately preceding the year in which the Change in Control occurs), which shall be paid when annual bonuses are paid to similarly situated executives; provided that, if the Release Execution Period begins in one taxable year and ends in another taxable year, payment shall not be made until the beginning of the second taxable year.
|
(b)
|
Executive shall be entitled, at the Company's expense, to twenty four (24) months of such medical, dental, hospitalization, life insurance, pension plan, profit-sharing, disability, employee benefits and such other similar employment privileges and benefits or perquisites as are afforded generally from time to time to other senior officers of the Company from and after Executive's Termination Date with the Company or a subsidiary of the Company.
|
(c)
|
For purposes of this Agreement, "Change in Control" shall mean the occurrence of any of the following after the Effective Date:
|
(i)
|
the sale of all, or substantially all of the assets of the Company;
|
(ii)
|
a merger, or recapitalization, or similar transaction which results in the shareholders of the Company immediately prior to such event owning less than sixty percent (60%) of the fair market value or the voting power of the surviving entity;
|
(iii)
|
the date during any twelve (12) month period that a majority of the Board is replaced by directors whose appointment is not endorsed by a majority of the members of the Board before the date of appointment or election;
|
(iv)
|
the acquisition, directly or indirectly, of the Beneficial Ownership (within the meaning of that term as it is used in Section 13(d) of the Securities Exchange Act of 1934, as amended) of fifty percent (50%) or more of the outstanding voting securities of the Company by any Person, entity or group. This definition shall not apply to the purchase of by underwriters in connection with a public offering of securities of the Company, or the purchase of shares of up to twenty five percent (25%) of any class of securities of the Company by a tax-qualified employee stock benefit plan.
|
(a)
|
The termination provision of this Agreement relied upon;
|
(b)
|
To the extent applicable, the facts and circumstances claimed to provide a basis for termination of the Executive's employment under the provision so indicated; and
|
(c)
|
The applicable Termination Date.
|
(a)
|
If the Executive's employment hereunder terminates on account of the Executive's death, the date of the Executive's death;
|
(b)
|
If the Executive's employment hereunder is terminated on account of the Executive's Disability, the date that it is determined that the Executive has a Disability;
|
(c)
|
If the Company terminates the Executive's employment hereunder for Cause, the date the Notice of Termination is delivered to the Executive;
|
(d)
|
If the Company terminates the Executive's employment hereunder without Cause, the date specified in the Notice of Termination, which shall be no less than thirty (30) days following the date on which the Notice of Termination is delivered; provided that, the Company shall have the option to provide the Executive with a lump sum payment equal to thirty (30) days' Base Salary in lieu of such notice, which shall be paid in a lump sum on the Executive's Termination Date and for all purposes of this Agreement, the Executive's Termination Date shall be the date on which such Notice of Termination is delivered;
|
(e)
|
If the Executive terminates his employment hereunder with or without Good Reason, the date specified in the Executive's Notice of Termination, which shall be no less than ninety (90) days following the date on which the Notice of Termination is delivered; provided that, the Company may waive all or any part of the ninety (90) day notice period for no consideration by giving written notice to the Executive and for all purposes of this Agreement, the Executive's Termination Date shall be the date determined by the Company; and
|
(f)
|
If the Executive's employment hereunder terminates because either party provides notice of non-renewal pursuant to Section 1, the Renewal Date immediately following the date on which the applicable party delivers notice of non-renewal.
|
(a)
|
Definition. For purposes of this Agreement, "Confidential Information" includes, but is not limited to, all information not generally known to the public, in spoken, printed, electronic or any other form or medium, relating directly or indirectly to: business processes, practices, methods, policies, plans, publications, documents, research, operations, services, strategies, techniques, agreements, contracts, terms of agreements, transactions, potential transactions, negotiations, pending negotiations, know-how, trade secrets, computer programs, computer software, applications, software design, web design, work-in-process, databases, manuals, records, articles, systems, material, sources of material, supplier information, vendor information, financial information, results, accounting information, accounting records, legal information, marketing information, advertising information, pricing information, credit information, design information, payroll information, staffing information, personnel information, employee lists, supplier lists, vendor lists, developments, reports, internal controls, security procedures, graphics, drawings, sketches, market studies, sales information, revenue, costs, formulae, notes, communications, algorithms, product plans, designs, styles, models, ideas, audiovisual programs, inventions, unpublished patent applications, original works of authorship, discoveries, experimental processes, experimental results, specifications, customer information, customer lists, client information, client lists, manufacturing information, factory lists, distributor lists, and buyer lists of the Company or its businesses or any existing or prospective customer, supplier, investor or other associated third party, or of any other person or entity that has entrusted information to the Company in confidence.
|
(b)
|
Company Creation and Use of Confidential Information. The Executive understands and acknowledges that the Company has invested, and continues to invest, substantial time, money, and specialized knowledge into developing its resources, creating a customer base, generating customer and potential customer lists, training its employees, and improving its offerings in the field of In-Vitro diagnostics and life science components and products. The Executive understands and acknowledges that as a result of these efforts, the Company has created, and continues to use and create Confidential Information. This Confidential Information provides the Company with a competitive advantage over others in the marketplace.
|
(c)
|
Disclosure and Use Restrictions. The Executive agrees and covenants: (i) to treat all Confidential Information as strictly confidential; (ii) not to directly or indirectly disclose, publish, communicate, or make available Confidential Information, or allow it to be disclosed, published, communicated, or made available, in whole or part, to any entity or person whatsoever (including other employees of the Company) not having a need to know and authority to know and use the Confidential Information in connection with the business of the Company and, in any event, not to anyone outside of the direct employ of the Company except as required in the performance of the Executive's authorized employment duties to the Company or with the prior consent of the Chairman of the Board acting on behalf of the Company in each instance (and then, such disclosure shall be made only within the limits and to the extent of such duties or consent); and (iii) not to access or use any Confidential Information, and not to copy any documents, records, files, media, or other resources containing any Confidential Information, or remove any such documents, records, files, media, or other resources from the premises or control of the Company, except as required in the performance of the Executive's authorized employment duties to the Company or with the prior consent of the Chairman of the Board acting on behalf of the Company in each instance (and then, such disclosure shall be made only within the limits and to the extent of such duties or consent). Nothing herein shall be construed to prevent disclosure of Confidential Information as may be required by applicable law or regulation, or pursuant to the valid order of a court of competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the extent of disclosure required by such law, regulation, or order. The Executive shall promptly provide written notice of any such order to the Chairman of the Board.
|
(d)
|
Notice of Immunity Under the Economic Espionage Act of 1996, as amended by the Defend Trade Secrets Act of 2016 ("DTSA"). Notwithstanding any other provision of this Agreement:
|
(i)
|
The Executive will not be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that:
|
(1)
|
is made (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (2) solely for the purpose of reporting or investigating a suspected violation of law; or
|
(2)
|
is made in a complaint or other document filed under seal in a lawsuit or other proceeding.
|
(ii)
|
If the Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Executive may disclose the Company's trade secrets to the Executive's attorney and use the trade secret information in the court proceeding if the Executive:
|
(1)
|
files any document containing trade secrets under seal; and
|
(2)
|
does not disclose trade secrets, except pursuant to court order.
|
(a)
|
the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year;
|
(b)
|
any reimbursement of an eligible expense shall be paid to the Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred; and
|
(c)
|
any right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.
|
(a)
|
The Executive's acceptance of employment with the Company and the performance of his duties hereunder will not conflict with or result in a violation of, a breach of, or a default under any contract, agreement, or understanding to which he is a party or is otherwise bound.
|
(b)
|
The Executive's acceptance of employment with the Company and the performance of his duties hereunder will not violate any non-solicitation, non-competition, or other similar covenant or agreement of a prior employer.
|
MERIDIAN BIOSCIENCE, INC.
|
|
|
|
By: /s/ John Kraeutler | |
Name: John A. Kraeutler | |
Title: Chairman, CEO | |
EXECUTIVE | |
|
|
Signature: /s/ John P. Kenny |
|
Print Name: John P. Kenny |
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end